Skip to main content
Premium Trial:

Request an Annual Quote

MD Anderson, BostonGene Ink Collaboration to Develop Cancer Diagnostics

NEW YORK – MD Anderson Cancer Center and BostonGene on Tuesday announced a collaboration to validate cancer biomarkers identified by MD Anderson researchers and develop clinical diagnostics based on those targets.

Under the agreement, which builds on existing collaborations between BostonGene and MD Anderson, the partners will conduct investigator-sponsored retrospective and prospective studies to identify and validate biomarkers for common and rare cancers. The two entities hope to develop multiple clinically actionable tests from this research and conduct clinical utility studies to support their incorporation into national guidelines and adoption into the standard of care.

The alliance will leverage BostonGene's computational platform and its CLIA-certified, CAP-accredited laboratory as well as the clinical and translational research expertise of MD Anderson's investigators.

"Through our collaboration with BostonGene, we will utilize multi-parameter discovery, big data analytics and computational support to advance and validate novel diagnostic and therapeutic biomarkers that we hope will guide physicians to deliver optimal care to each patient," Funda Meric-Bernstam, chair of investigational cancer therapeutics at MD Anderson, said in a statement.

MD Anderson is eligible to receive undisclosed payments from BostonGene if it meets certain clinical milestones and commercial sales goals for the developed tests. The partners didn't disclose further financial details of the deal.

BostonGene and MD Anderson recently inked a laboratory services agreement to offer its Tumor Portrait test and data analytics platform to oncologists at the cancer center.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.